To our knowledge, this is the first study conducted in patients with cHL aimed at unveiling potential associations between BMI, incidence of irAEs, response outcomes and survival upon therapeutic PD-1 blockade with single agent nivolumab. Here, PDCD1 is linked to classic Hodgkin lymphoma.